Panagora Asset Management Inc. Sells 114,816 Shares of Omnicell, Inc. $OMCL

Key Points

• Panagora Asset Management Inc. sold 114,816 shares of Omnicell, Inc. (OMCL), reducing its position by 70.3% in the first quarter, leaving them with 48,411 shares valued at approximately $1.69 million.
• Omnicell's recent earnings report showed earnings per share (EPS) of $0.45, exceeding analyst expectations of $0.30 and marking a revenue increase of 5.0% year-over-year.
• Investment analysts have mixed reviews on Omnicell, with an average rating of "Moderate Buy" and a price target averaging around $46.71 after several recent upgrades and downgrades.

Panagora Asset Management Inc. trimmed its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 70.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,411 shares of the company's stock after selling 114,816 shares during the period. Panagora Asset Management Inc. owned about 0.10% of Omnicell worth $1,692,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Diversified Trust Co increased its holdings in Omnicell by 2.3% during the 1st quarter. Diversified Trust Co now owns 22,660 shares of the company's stock worth $792,000 after purchasing an additional 513 shares in the last quarter. Bridge City Capital LLC lifted its stake in Omnicell by 1.6% during the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock valued at $1,403,000 after acquiring an additional 650 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Omnicell by 4.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company's stock valued at $553,000 after buying an additional 696 shares during the last quarter. EntryPoint Capital LLC boosted its position in shares of Omnicell by 21.6% during the 1st quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock valued at $233,000 after acquiring an additional 1,184 shares during the last quarter. Finally, Wakefield Asset Management LLLP increased its holdings in shares of Omnicell by 8.1% in the first quarter. Wakefield Asset Management LLLP now owns 25,517 shares of the company's stock worth $892,000 after buying an additional 1,906 shares during the period. Institutional investors own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research reports. Piper Sandler decreased their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Wall Street Zen lowered Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Wells Fargo & Company raised their target price on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Finally, Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Price Performance

Shares of NASDAQ OMCL traded up $0.19 during trading on Monday, hitting $32.30. The company had a trading volume of 224,444 shares, compared to its average volume of 564,652. The company has a market cap of $1.48 billion, a P/E ratio of 64.60, a PEG ratio of 7.01 and a beta of 0.82. The business's 50-day moving average is $30.44 and its 200 day moving average is $31.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities research analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.